Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
- PMID: 8837607
- DOI: 10.1038/nm1096-1096
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
Erratum in
- Nat Med 1996 Nov;2(11):1267
Abstract
Inadequate presentation of tumor antigens by host professional antigen-presenting cells (APCs), including dendritic cells (DCs), is one potential mechanism for the escape of tumors from the host immune system. Here, we show that human cancer cell lines release a soluble factor or factors that dramatically affect DC maturation from precursors without affecting the function of relatively mature DCs. One factor responsible for these effects was identified as vascular endothelial growth factor (VEGF). Thus, VEGF may play a broader role in the pathogenesis of cancer than was previously thought, and therapeutic blockade of VEGF action may improve prospects for immunotherapy as well as inhibit tumor neovasculature.
Similar articles
-
VEGF as a mediator of tumor-associated immunodeficiency.Immunol Res. 2001;23(2-3):263-72. doi: 10.1385/IR:23:2-3:263. Immunol Res. 2001. PMID: 11444391 Review.
-
Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells.J Immunol. 1998 Feb 1;160(3):1224-32. J Immunol. 1998. PMID: 9570538
-
Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.Cancer Res. 2003 Jun 15;63(12):3403-12. Cancer Res. 2003. PMID: 12810677
-
Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo.J Immunol. 1999 Sep 15;163(6):3260-8. J Immunol. 1999. PMID: 10477595
-
The regulation of blood vessel growth by vascular endothelial growth factor.Ann N Y Acad Sci. 1995 Mar 27;752:246-56. doi: 10.1111/j.1749-6632.1995.tb17435.x. Ann N Y Acad Sci. 1995. PMID: 7538737 Review. No abstract available.
Cited by
-
Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.Front Immunol. 2024 Sep 13;15:1424396. doi: 10.3389/fimmu.2024.1424396. eCollection 2024. Front Immunol. 2024. PMID: 39346924 Free PMC article. Review.
-
Enhanced efficacy of combined VEGFR peptide-drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma.Sci Rep. 2024 Sep 17;14(1):21728. doi: 10.1038/s41598-024-72907-w. Sci Rep. 2024. PMID: 39289512 Free PMC article.
-
The complexity of immune evasion mechanisms throughout the metastatic cascade.Nat Immunol. 2024 Oct;25(10):1793-1808. doi: 10.1038/s41590-024-01960-4. Epub 2024 Sep 16. Nat Immunol. 2024. PMID: 39285252 Review.
-
PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model.Clin Exp Metastasis. 2024 Sep 5. doi: 10.1007/s10585-024-10309-y. Online ahead of print. Clin Exp Metastasis. 2024. PMID: 39231916
-
Targeting the tumour vasculature: from vessel destruction to promotion.Nat Rev Cancer. 2024 Oct;24(10):655-675. doi: 10.1038/s41568-024-00736-0. Epub 2024 Aug 29. Nat Rev Cancer. 2024. PMID: 39210063 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous